Intestinal microbiota, pathophysiology and translation to probiotic use in patients with irritable bowel syndrome

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 3, 2012, Pages 383-398

  Almansa, Cristina ^a   Agrawal, Anurag ^b   Houghton, Lesley A ^a,c  

^a MAYO CLINIC   (United States)

^b DONCASTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

immune system; inflammation; irritable bowel syndrome; motility; probiotics; visceral sensitivity

Indexed keywords

LACTEOL FORT; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VSL3;

BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL PRACTICE; COMMON COLD; DISEASE MODEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG USE; EPISTAXIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT FUNCTION; HUMAN; IMMUNOPATHOGENESIS; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS JOHNSONII; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; MICROCOCCUS LUTEUS; NONHUMAN; NOSE INFECTION; PATHOPHYSIOLOGY; RESPIRATORY TRACT DISEASE; REVIEW; SKIN DEFECT; STREPTOCOCCUS THERMOPHILUS; SYMPTOM; THORAX PAIN;

EID: 84861750253     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130(5), 1480-1491 (2006
2. Schmulson M, Lee OY, Chang L, Naliboff B, Mayer EA. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am. J. Gastroenterol. 94(10), 2929-2935 (1999 (Pubitemid 29482760)
3. Houghton LA. Bloating in constipation: releVance of intraluminal gas handling. Best Pract. Res. Clin. Gastroenterol. 25(1), 141-150 (2011
4. Chitkara DK, Van Tilburg MA, Blois- Martin N, Whitehead WE. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am. J. Gastroenterol. 103(3), 765-74; quiz 775 (2008 (Pubitemid 351406002)
5. Saito YA, Talley NJ. Genetics of irritable bowel syndrome. Am. J. Gastroenterol. 103(8), 2100-2104; quiz 2105 (2008
6. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 136(6), 1979-1988 (2009
7. Levy RL, Olden KW, Naliboff BD et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 130(5), 1447-1458 (2006
8. Sadik R, Stotzer PO, Simrén M, Abrahamsson H. Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre. Neurogastroenterol. Motil. 20(3), 197-205 (2008 (Pubitemid 351197397)
9. Agrawal A, Houghton LA, Reilly B, Morris J, Whorwell PJ. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am. J. Gastroenterol. 104(8), 1998-2004 (2009
10. Camilleri M, McKinzie S, Busciglio I et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 6(7), 772-781 (2008
11. Ravi K, Bharucha AE, Camilleri M, Rhoten D, Bakken T, Zinsmeister AR. Phenotypic variation of colonic motor functions in chronic constipation. Gastroenterology 138(1), 89-97 (2010
12. Spiller R, Aziz Q, Creed F et al.; Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56(12), 1770-1798 (2007 (Pubitemid 350206308)
13. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am. J. Gastroenterol. 96(5), 1499-1506 (2001 (Pubitemid 32455081)
14. Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 115(5), 1263-1271 (1998 (Pubitemid 28485619)
15. Posserud I, Syrous A, Lindström L, Tack J, Abrahamsson H, Simrén M. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 133(4), 1113-1123 (2007 (Pubitemid 47494459)
16. Mayer EA, Bradesi S, Chang L, Spiegel BM, Bueller JA, Naliboff BD. Functional GI disorders: from animal models to drug development. Gut 57(3), 384-404 (2008 (Pubitemid 351288106)
17. Agrawal A, Houghton LA, Lea R, Morris J, Reilly B, Whorwell PJ. Bloating and distention in irritable bowel syndrome: the role of visceral sensation. Gastroenterology 134(7), 1882-1889 (2008 (Pubitemid 351783263)
18. Spiller R, Garsed K. The role of inflammation in irritable bowel syndrome. J. Clin. Gastroenterology. 41, 844-849 (2009
19. Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1 beta in postinfectious irritable bowel syndrome. Gut 52, 523-526 (2003 (Pubitemid 36363405)
20. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig. Dis. Sci. 38(9), 1590-1595 (1993 (Pubitemid 23271411)
21. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 132(1), 26-37 (2007 (Pubitemid 46108761)
22. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am. J. Gastroenterol. 98(7), 1578-1583 (2003 (Pubitemid 36875351)
23. Dinan TG, Quigley EM, Ahmed SM et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 130(2), 304-311 (2006 (Pubitemid 43202030)
24. Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 132(3), 913-920 (2007 (Pubitemid 46440872)
25. Motomura Y, Ghia JE, Wang H et al. Enterochromaffin cell and 5-hydroxytryptamine responses to the same infectious agent differ in Th1 and Th2 dominant environments. Gut 57(4), 475-481 (2008 (Pubitemid 351442531)
26. Park JH, Rhee PL, Kim G et al. Enteroendocrine cells correlate with visceral sensitivity in irritable bowel syndrome. Neurogastroenterol. Motil. 18, 539-546 (2006
27. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126(3), 693-702 (2004 (Pubitemid 38298317)
28. Schoepfer AM, Schaffer T, Seibold-Schmid B, Müller S, Seibold F. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol. Motil. 20(10), 1110-1118 (2008
29. Langhorst J, Junge A, Rueffer A et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am. J. Gastroenterol. 104(2), 404-410 (2009
30. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of Toll-like receptors in patients with irritable bowel syndrome. Am. J. Gastroenterol. 106(2), 329-336 (2011
31. Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: the unseen majority. Proc. Natl Acad. Sci. USA 95(12), 6578-6583 (1998 (Pubitemid 28278022)
32. Walter J, Ley R. The human gut microbiome: ecology and recent evolutionary changes. Annu. Rev. Microbiol. 65, 411-429 (2011
33. Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science 308(5728), 1635-1638 (2005 (Pubitemid 40807514)
34. Dominguez-Bello MG, Costello EK, Contreras M et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl Acad. Sci. USA 107(26), 11971-11975 (2010
35. Zivkovic AM, German JB, Lebrilla CB, Mills DA. Human milk glycobiome and its impact on the infant gastrointestinal microbiota. Proc. Natl Acad. Sci. USA 108(Suppl. 1), 4653-4658 (2011
36. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 361(9356), 512-519 (2003 (Pubitemid 36173720)
37. Dominguez-Bello MG, Blaser MJ, Ley RE, Knight R. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 140(6), 1713-1719 (2011
38. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig. Liver Dis. 41(12), 850-853 (2009
39. Abrams GD, Bishop JE. Effect of the normal microbial flora on gastrointestinal motility. Proc. Soc. Exp. Biol. Med. 126(1), 301-304 (1967
40. Caenepeel P, Janssens J, Vantrappen G, Eyssen H, Coremans G. Interdigestive myoelectric complex in germ-free rats. Dig. Dis. Sci. 34(8), 1180-1184 (1989 (Pubitemid 19202111)
41. Husebye E, Hellström PM, Midtvedt T. Intestinal microflora stimulates myoelectric activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex. Dig. Dis. Sci. 39(5), 946-956 (1994 (Pubitemid 24188834)
42. Husebye E, Hellström PM, Sundler F, Chen J, Midtvedt T. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am. J. Physiol. Gastrointest. Liver Physiol. 280(3), G368-G380 (2001
43. Lesniewska V, Rowland I, Laerke HN, Grant G, Naughton PJ. Relationship between dietary-induced changes in intestinal commensal microflora and duodenojejunal myoelectric activity monitored by radiotelemetry in the rat in vivo. Exp. Physiol. 91(1), 229-237 (2006
44. Verdú EF, Bercik P, Verma-Gandhu M et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55(2), 182-190 (2006 (Pubitemid 43117275)
45. Dupont JR, Jervis HR, Sprinz H. Auerbach's plexus of the rat cecum in relation to the germfree state. J. Comp. Neurol. 125(1), 11-18 (1965
46. Uribe A, Alam M, Johansson O, Midtvedt T, Theodorsson E. Microflora modulates endocrine cells in the gastrointestinal mucosa of the rat. Gastroenterology 107(5), 1259-1269 (1994 (Pubitemid 24328261)
47. Arantes RM, Nogueira AM. Distribution of enteroglucagon- and peptide YYimmunoreactive cells in the intestinal mucosa of germ-free and conventional mice. Cell Tissue Res. 290(1), 61-69 (1997 (Pubitemid 27460126)
48. Kunze WA, Mao YK, Wang B et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J. Cell. Mol. Med. 13(8B), 2261-2270 (2009
49. Falk PG, Hooper LV, Midtvedt T, Gordon JI. Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Microbiol. Mol. Biol. Rev. 62(4), 1157-1170 (1998 (Pubitemid 28558295)
50. Sudo N, Chida Y, Aiba Y et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J. Physiol. 558(Pt 1), 263-275 (2004 (Pubitemid 39077406)
51. Bailey MT, Coe CL. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev. Psychobiol. 35(2), 146-155 (1999 (Pubitemid 29416198)
52. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136(6), 2003-2014 (2009
53. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat. Rev. Gastroenterol. Hepatol. 6(5), 306-314 (2009
54. Mendall MA, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur. J. Gastroenterol. Hepatol. 10(1), 59-62 (1998 (Pubitemid 28085501)
55. Wynne AG, McCartney AL, Brostoff J, Hudspith BN, Gibson GR. An in vitro assessment of the effects of broad-spectrum antibiotics on the human gut microflora and concomitant isolation of a Lactobacillus plantarum with anti-Candida activities. Anaerobe 10(3), 165-169 (2004 (Pubitemid 38789117)
56. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann. Intern. Med. 145(8), 557-563 (2006 (Pubitemid 46780934)
57. Pimentel M, Lembo A, Chey WD et al.; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med. 364(1), 22-32 (2011
58. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol. 98(2), 412-419 (2003 (Pubitemid 36232393)
59. Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am. J. Gastroenterol. 103(4), 958-963 (2008 (Pubitemid 351501116)
60. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56(6), 802-808 (2007 (Pubitemid 46854194)
61. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 7(12), 1279-1286 (2009
62. Chatterjee S, Park S, Low K, Kong Y, Pimentel M. The degree of breath methane production in IBS correlates with the severity of constipation. Am. J. Gastroenterol. 102(4), 837-841 (2007 (Pubitemid 46496615)
63. Grover M, Kanazawa M, Palsson OS et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol. Motil. 20(9), 998-1008 (2008
64. Pimentel M, Lin HC, Enayati P et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am. J. Physiol. Gastrointest. Liver Physiol. 290(6), G1089-G1095 (2006 (Pubitemid 43788289)
65. Lasser RB, Bond JH, Levitt MD. Role of intestinal gas in functional abdominal pain. N. Eng. J. Med. 293, 524-526 (1975
66. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 48(1), 14-19 (2001 (Pubitemid 32042636)
67. Maxton DG, Martin DF, Whorwell PJ, Godfrey M. Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut 32(6), 662-664 (1991
68. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 352(9135), 1187-1189 (1998 (Pubitemid 28458534)
69. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 156(Pt 11), 3205-3215 (2010
70. Kassinen A, Krogius-Kurikka L, Mäkivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133(1), 24-33 (2007 (Pubitemid 47031125)
71. Mättö J, Maunuksela L, Kajander K et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - a longitudinal study in IBS and control subjects. FEMS Immunol. Med. Microbiol. 43(2), 213-222 (2005 (Pubitemid 40170291)
72. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig. Dis. Sci. 55(2), 392-397 (2010
73. Noor SO, Ridgway K, Scovell L et al. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol. 10, 134 (2010
74. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica 5(3), 185-194 (1982 (Pubitemid 13228114)
75. Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J. Gastroenterol. 10(12), 1802-1805 (2004
76. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil. 22(5), 512-519, e114 (2010
77. Quigley EM. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, antiinflammatory therapies. Gastroenterol. Clin. North Am. 40(1), 207-222 (2011
78. Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science 308(5728), 1635-1638 (2005 (Pubitemid 40807514)
79. Chaudhary NA, Truelove SC. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q. J. Med. 31, 307-322 (1962
80. McKendrick MW, Read NW. Irritable bowel syndrome - post Salmonella infection. J. Infect. 29(1), 1-3 (1994 (Pubitemid 24243103)
81. Gwee KA, Graham JC, McKendrick MW et al. Psychometric scores and persistence of irritable bowel after infectious diarrhea. Lancet 347(8995), 150-153 (1996 (Pubitemid 26025154)
82. Gwee KA, Leong YL, Graham C et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 44(3), 400-406 (1999 (Pubitemid 29119338)
83. Parry SD, Barton JR, Welfare MR. Factors associated with the development of post-infectious functional gastrointestinal diseases: does smoking play a role? Eur. J. Gastroenterol. Hepatol. 17(10), 1071-1075 (2005 (Pubitemid 41424000)
84. Houghton LA, Atkinson W, Lockhart C, Whorwell PJ, Keevil B. Sigmoid-colonic motility in health and irritable bowel syndrome: a role for 5-hydroxytryptamine. Neurogastroenterol. Motil. 19(9), 724-731 (2007 (Pubitemid 47312399)
85. Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br. J. Pharmacol. 141(8), 1285-1293 (2004 (Pubitemid 38638817)
86. Dunlop SP, Coleman NS, Blackshaw E et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 3(4), 349-357 (2005 (Pubitemid 40488343)
87. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 53(8), 1096-1101 (2004
88. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J. Gastroenterol. Hepatol. 23(11), 1689-1694 (2008
89. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47(6), 804-811 (2000
90. Weston AP, Biddle WL, Bhatia PS, Miner PB. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig. Dis. Sci. 38, 1590-1595 (1993 (Pubitemid 23271411)
91. Söderholm JD, Yang PC, Ceponis P et al. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 123(4), 1099-1108 (2002
92. Piche T, Saint-Paul MC, Dainese R et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 57(4), 468-473 (2008 (Pubitemid 351442529)
93. Guilarte M, Santos J, de Torres I et al. Diarrhea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 56(2), 203-209 (2007
94. Hamilton-Miller JM, Gibson GR, Bruck W. Some insights into the derivation and early uses of the word 'probiotic'. Br. J. Nutr. 90(4), 845 (2003 (Pubitemid 37270769)
95. Metchnikoff E. The Prolongation of Life: Optimistic Studies. The English Translation Edit by P Chalmers Mitchell. The Knickerbocker Press, GP Putnam's Sons, NY, USA, and London, UK (1908
96. Cheplin HA, Rettger LF. Studies on the Transformation of theintestinal flora, with special reference to the implantation of Bacillus acidophilus: I. Feeding experiments with albino rats. Proc. Natl Acad. Sci. USA 6(7), 423-426 (1920
97. Cheplin HA, Rettger LF. Studies on the transformation of the intestinal flora, with special reference to the implantation of Bacillus acidophilus: II. Feeding experiments on man. Proc. Natl Acad. Sci. USA 6(12), 704-705 (1920
98. Kollath W. [Nutrition and the tooth system; general review with special reference to vitamins]. Ernahrung und Zahnsystem. Dtsch. Zahnarztl. Z. 8(11), 7-16 (1953
99. Parker RB. Probiotics. The other half of the antibiotics story. Anim. Nutr. Heath. 29, 4-8 (1974
100. Fuller R. Probiotics in man and animals. J. Appl. Bacteriol. 66(5), 365-378 (1989
101. Joint FAO/WHO Working Group. Report on drafting guidelines for the evaluation of probiotics in food. London, ON, Canada, 30 April-1 May 2002.
102. Shanahan F. Probiotics in perspective. Gastroenterology 139(6), 1808-1812 (2010
103. Rabot S, Rafter J, Rijkers GT, Watzl B, Antoine JM. Guidance for substantiating the evidence for beneficial effects of probiotics: impact of probiotics on digestive system metabolism. J. Nutr. 140(3), 677S-689S (2010
104. Shukla S, Shukla A, Mehboob S, Guha S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment. Pharmacol. Ther. 33(6), 662-671 (2011
105. Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am. J. Gastroenterol. 91(8), 1579-1585 (1996 (Pubitemid 26269174)
106. Sinn DH, Song JH, Kim HJ et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig. Dis. Sci. 53(10), 2714-2718 (2008
107. Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol. 95(5), 1231-1238 (2000 (Pubitemid 30263518)
108. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 13(10), 1143-1147 (2001 (Pubitemid 33015878)
109. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig. Dis. Sci. 47(11), 2615-2620 (2002 (Pubitemid 35305475)
110. Ligaarden SC, Axelsson L, Naterstad K, Lydersen S, Farup PG. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol. 10, 16 (2010
111. Klingberg TD, Pedersen MH, Cencic A, Budde BB. Application of measurements of transepithelial electrical resistance of intestinal epithelial cell monolayers to evaluate probiotic activity. Appl. Environ. Microbiol. 71(11), 7528-7530 (2005 (Pubitemid 43194247)
112. O'Mahony L, McCarthy J, Kelly P et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128(3), 541-551 (2005 (Pubitemid 40585355)
113. Whorwell PJ, Altringer L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 101(7), 1581-1590 (2006 (Pubitemid 43980633)
114. Guyonnet D, Chassany O, Ducrotte P et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on bloating and health-related quality of life in irritable bowel syndrome (IBS) adult patients - a randomized, double-blind, controlled trial. Aliment. Pharmacol. Ther. 26, 475-486 (2007 (Pubitemid 47063138)
115. Agrawal A, Houghton LA, Morris J et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 29(1), 104-114 (2009
116. Marteau P, Cuillerier E, Meance S et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment. Pharmacol. Ther. 16(3), 587-593 (2002 (Pubitemid 34214540)
117. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life - a double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 33(10), 1123-1132 (2011
118. Kim HJ, Camilleri M, McKinzie S et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 17(7), 895-904 (2003 (Pubitemid 36459602)
119. Kim HJ, Vazquez Roque MI, Camilleri M et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol. Motil. 17(5), 687-696 (2005 (Pubitemid 41400717)
120. Guandalini S, Magazzu G, Chiaro A et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo- controlled, double blind, crossover study. J. Pediatr. Gastroenterol. Nutr. 51(1), 24-30 (2010
121. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment. Pharmacol. Ther. 22(5), 387-394 (2005 (Pubitemid 41248105)
122. Kajander K, Myllyluoma E, Rajilic-Stojanovic M et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment. Pharmacol. Ther. 27(1), 48-57 (2008 (Pubitemid 350212625)
123. Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59(3), 325-332 (2010
124. Lu CL, Chang FY. Placebo effect in patients with irritable bowel syndrome. J. Gastroenterol. Hepatol. 26(Suppl. 3), 116-118 (2011
125. Ringel Y, Ringel-Kulka T, Maier D et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi07 versus placebo for the symptoms of bloating in patients with functional bowel disorders - a double blind study. J. Clin. Gastroenterol. 45(6), 518-525 (2011
126. Besselink MG, Van Santvoort HC, Buskens E et al.; Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371(9613), 651-659 (2008
127. Williams MD, Ha CY, Ciorba MA. Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations. J. Clin. Gastroenterol. 44(9), 631-636 (2010
128. ISAPP. 6th Meeting of the International Scientific Association of Probiotics and Prebiotics. London, ON, Canada, 9-11 November 2008.
129. Roberfroid M, Gibson GR, Hoyles L et al. Prebiotic effects: metabolic and health benefits. Br. J. Nutr. 104(Suppl. 2), S1-S63 (2010
130. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 29(5), 508-518 (2009
131. Paineau D, Payen F, Panserieu S et al. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br. J. Nutr. 99(2), 311-318 (2008
132. Andriulli A, Neri M, Loguercio C et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J. Clin. Gastroenterol. 42(Suppl. 3, Pt 2), S218-S223 (2008
133. Bittner AC, Croffut RM, Stranahan MC. Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, doubleblind clinical study. Clin. Ther. 27(6), 755-761 (2005 (Pubitemid 41583523)
134. Bittner AC, Croffut RM, Stranahan MC, Yokelson TN. Prescript-assist probioticprebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-year extension of a previously published controlled clinical trial. Clin. Ther. 29(6), 1153-1160 (2007 (Pubitemid 47198883)
135. Colecchia A, Vestito A, La Rocca A, Pasqui F, Nikiforaki A, Festi D; Symbiotic Study Group. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol. Dietol. 52(4), 349-358 (2006 (Pubitemid 46166443)
136. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin. J. Dig. Dis. 5(4), 169-174 (2004 (Pubitemid 40028569)
137. Dughera L, Elia C, Navino M, Cisarò F; ARMONIA Study Group. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Biomed. 78(2), 111-116 (2007
138. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J. Nutr. 125(6), 1401-1412 (1995
139. Verdú EF, Bercík P, Bergonzelli GE et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 127(3), 826-837 (2004 (Pubitemid 39208415)
140. Verdú EF, Bercik P, Verma-Gandhu M et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55(2), 182-190 (2006 (Pubitemid 43117275)
141. Kamiya T, Wang L, Forsythe P et al. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 55(2), 191-196 (2006 (Pubitemid 43117276)
142. McKernan DP, Fitzgerald P, Dinan TG, Cryan JF. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol. Motil. 22(9), 1029-35, e268 (2010
143. Ait-Belgnaoui A, Han W, Lamine F et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 55(8), 1090-1094 (2006 (Pubitemid 44085673)
144. Eutamene H, Lamine F, Chabo C et al. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J. Nutr. 137(8), 1901-1907 (2007 (Pubitemid 47292737)
145. Rousseaux C, Thuru X, Gelot A et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 13(1), 35-37 (2007 (Pubitemid 46067383)
146. Schultz M, Linde HJ, Lehn N et al. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J. Dairy Res. 70(2), 165-173 (2003 (Pubitemid 36599405)
147. Pessi T, Sütas Y, Hurme M, Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin. Exp. Allergy 30(12), 1804-1808 (2000 (Pubitemid 32011762)
148. Latvala S, Miettinen M, Kekkonen RA, Korpela R, Julkunen I. Lactobacillus rhamnosus GG and Streptococcus thermophilus induce suppressor of cytokine signalling 3 (SOCS3) gene expression directly and indirectly via interleukin-10 in human primary macrophages. Clin. Exp. Immunol. 165(1), 94-103 (2011
149. Hart AL, Lammers K, Brigidi P et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53(11), 1602-1609 (2004 (Pubitemid 39434103)
150. Otte JM, Podolsky DK. Functional modulation of enterocytes by Gram-positive and Gram-negative microorganisms. Am. J. Physiol. Gastrointest. Liver Physiol. 286(4), G613-G626 (2004 (Pubitemid 38374981)
151. Pozo-Rubio T, Mujico JR, Marcos A et al. Immunostimulatory effect of faecal Bifidobacterium species of breast-fed and formula-fed infants in a peripheral blood mononuclear cell/Caco-2 co-culture system. Br. J. Nutr. 106(8), 1216-1223 (2011
152. Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 47(1), 79-87 (2000 (Pubitemid 30430415)
153. Fujii T, Ohtsuka Y, Lee T et al. Bifidobacterium breve enhances transforming growth factor beta1 signaling by regulating Smad7 expression in preterm infants. J. Pediatr. Gastroenterol. Nutr. 43(1), 83-88 (2006 (Pubitemid 44022391)
154. Iyer C, Kosters A, Sethi G, Kunnumakkara AB, Aggarwal BB, Versalovic J. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling. Cell. Microbiol. 10(7), 1442-1452 (2008 (Pubitemid 351837265)
155. von der Weid T, Bulliard C, Schiffrin EJ. Induction by a lactic acid bacterium of a population of CD4+ T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. Clin. Diagn. Lab. Immunol. 8(4), 695-701 (2001 (Pubitemid 32613693)
156. Otte JM, Mahjurian-Namari R, Brand S, Werner I, Schmidt WE, Schmitz F. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr. Cancer 61(1), 103-113 (2009
157. Seth A, Yan F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinasedependent mechanism. Am. J. Physiol. Gastrointest. Liver Physiol. 294(4), G1060-G1069 (2008 (Pubitemid 351520059)
158. Johnson-Henry KC, Donato KA, Shen-Tu G, Gordanpour M, Sherman PM. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect. Immun. 76(4), 1340-1348 (2008 (Pubitemid 351561979)
159. O'SulliVan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig. Liver Dis. 32(4), 294-301 (2000 (Pubitemid 30445067)
160. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J. Pediatr. 147(2), 197-201 (2005 (Pubitemid 41207833)
161. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment. Pharmacol. Ther. 25(2), 177-184 (2007 (Pubitemid 46046374)
162. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - a double blind, placebo-controlled, randomized study. Clin. Nutr. 24(6), 925-931 (2005 (Pubitemid 41782449)
163. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol. Clin. Biol. 32(2), 147-152 (2008 (Pubitemid 351637577)
164. Simrén M, Ohman L, Olsson J et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - a randomized, double-blind, controlled study. Aliment. Pharmacol. Ther. 31(2), 218-227 (2010
165. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J. Clin. Gastroenterol. 45(8), 679-683 (2011
166. Guslandi M. Treatment of irritable bowel syndrome with Saccharomyces boulardii. J. Clin. Gastroenterol. 45(8), 740-741; author reply 741 (2011)